On March 11, 2019, the Company received a loan for $50,000 and entered into a promissory note and security agreement with a third party. The loan was secured with ECAP-C machines. The due date of the loan was the earlier of April 30, 2019 or the closing of the transaction with the third party. Interest shall accrue at a rate of 6% per annum from April 11, 2019 until paid in full.

On May 1, 2019, the transaction closed and agreements were executed. The Company repaid the $50,000 upon closing of the transaction.

On October 17, 2019, the Company executed a secured note with a related party for $100,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 2 million shares of IBX common stock. The interest expense for the year ended December 31, 2019 was $3,400. The Company recorded a debt discount for debt issue costs consisting of shares of IBX valued at $51,400.

On October 17, 2019, the Company executed a secured note with an individual for $ 50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.015 per share with 1 million shares of IBX common stock. The interest expense for the year ended December 31, 2019 was $1,600. The Company recorded a debt discount for debt issue costs consisting of shares of IBX valued at $25,700.

Notes payable	$	150,000
Less: Discounts on notes payable		(72,000	)
Notes payable, net of discounts	$	78,000

During the year ended December 31, 2019, the Company recorded amortization of $5,100. The balance of the debt discount was $72,000 as of December 31, 2019.